THT 2026: What to Expect in Boston

THT 2026 kicks off next week in Boston, MA, with the main meeting running from March 2 to 4. It’ll be preceded by a hands-on training day on March 1, which registered attendees can participate in for free.

I’ll be there to cover research presentations and discussions on the latest device- and technology-based innovations in heart failure (HF). You can reach me via email in the lead-up to the meeting or on-site, either to talk about any of the sessions or just to say hello. I’m looking forward to connecting with many of you there.

The first day of THT 2026 will bring abstract sessions focused on cardiogenic shock, outpatient monitoring of heart failure, durable left ventricular assist devices (LVADs), and heart transplant, as well as spotlight sessions on treating acute HF across the spectrum of the healthcare system, remote patient monitoring, and novel approaches to treating cardiomyopathies.

The opening session in the Main Arena is set to include talks on heart replacement therapies of the future, xenotransplant, and durable mechanical circulatory support, followed by a conversation with Apoorva Mehta, founder of Instacart.

Later on that first day is the first late-breaking clinical science session digging into fresh data on various approaches to managing HF. Also, two debates will tackle the role of precision medicine by deep phenotyping in characterizing the heterogeneity of heart failure with preserved ejection fraction (HFpEF) and whether transcatheter edge-to-edge repair (TEER) should be performed for moderate mitral regurgitation in HF. Monday closes out with a session on the impact of artificial intelligence (AI) in HF care.

Tuesday brings focused sessions on advanced hemodynamics and gene therapy and spotlight sessions on acute decompensated HF, electrical therapies for HF, LV reverse remodeling as a target for treating heart failure with reduced ejection fraction (HFrEF), HF controversies in structural heart disease, advances in durable LVAD technologies, and—in partnership with the American Society for Artificial Internal Organs—organ preservation. There will be a fellows abstract competition and other abstract sessions on structural heart interventions in HF, cardiogenic shock, HFrEF, acute decompensated HF, temporary mechanical circulatory support, and HFpEF.

The Main Arena that day will feature a first-in-human/early feasibility studies abstract session and the second late-breaking clinical science session, along with others covering advances in the treatment of cardiogenic shock, percutaneous ventricular assist device technology, device-based therapies for HFpEF, atrial fibrillation, and complex cases in cardiomyopathy.

The last day of the meeting, on Wednesday, involves challenging cases from fellows and spotlight sessions on right ventricular function in HF, interatrial shunting, HF devices, and clinical evidence development using real-world data. There will be a third late-breaking clinical science session as well as the Shark Tank Innovation Competition.

Overall, the THT 2026 schedule includes 20 presentations dedicated to first-in-human/early feasibility studies and 24 late-breaking clinical science presentations. There will also be poster sessions and a number of academic satellite programs on Monday and Tuesday.

“Together, these sessions deliver an unparalleled look at the discoveries, technologies, and clinical advances shaping the next era of heart failure treatment,” said Juan Granada, MD, president and CEO of the Cardiovascular Research Foundation, in an email.